Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akeso
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
≥18 years old and ≤75 years old (at the time consent is obtained).
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Has a life expectancy of at least 3 months.
Has a histologically confirmed diagnosis of squamous NSCLC.
Has Stage IIIB/C or IV NSCLC (American Joint Committee on Cancer \[AJCC\]).
Has no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Has adequate organ function.
You may not be if
Histological diagnosis of non-squamous NSCLC.
Has EGFR-sensitive mutations or ALK gene translocations.
Known ROS1 rearrangement, MET exon 14 skipping mutation, or RET gene fusion positivite.
Is currently participating in a study of an investigational agent or using an investigational device.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment.
Has undergone major surgery within 30 days of Study Day 1.
Has known active central nervous system (CNS) metastases.
Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Has an active infection requiring systemic therapy.
Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected).
History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
Has received a live virus vaccine within 30 days of the planned first dose of study therapy.
Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject.
Clareo Health | AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
